Research programme: anti-prostate cancer therapeutics - Stem Cell Therapeutics/The University of York
Latest Information Update: 29 Nov 2021
At a glance
- Originator The University of York
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 17 Nov 2021 Trillium Therapeutics Inc has been acquired by Pfizer
- 28 Jul 2018 No recent reports of development identified for preclinical development in Prostate-cancer in United Kingdom (Parenteral)
- 02 Jun 2014 Stem Cell Therapeutics is now called Trillium Therapeutics